Celsion, a drug-development company based in Columbia, MD, has been awarded a $200,000 Phase I SBIR grant from the NIH for its low heat-activated liposomes, which the company says enables delivery of drugs directly to cancer sites. The grant will support formulation development and preclinical studies in collaboration with Duke University. "NIH's support of Celsion's unique research focus is evident with this grant and represents a continuation of the Institute's interest in the value of our platform heat sensitive liposomal technology to treat certain difficult cancers; most notably reflected in our ThermoDox clinical program," Michael Tardugno, Celsion's president and CEO says in a statement. We reported on ThermoDox Aug. 25, when the drug was granted fast-track status by the FDA. Celsion release